SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.80), $0.15 worse than the analyst estimate of ($1.65). Revenue for the quarter came in at $7.9 million versus the consensus estimate of $5.11 million.

FINANCIAL GUIDANCE

Based upon the Company\'s current operating plan, Sage anticipates that its existing cash, cash equivalents and marketable securities, anticipated funding from ongoing collaborations, and estimated revenues, will support its operations into 2026.​
The Company does not anticipate receipt of any additional milestone payments from collaborations in the remainder of 2024.
The Company anticipates operating expenses will decrease in 2024 relative to 2023.​
With the availability of ZURZUVAE in the U.S. as an additional treatment for women with PPD, the Company anticipates ZULRESSO revenues will continue to decrease over time.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.